Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study

被引：0
|
作者：
Maher, Keri Renee
Schafer, Danielle
Schaar, Dale
Sabo, Roy
Bandyopadhyay, Dipankar
Grant, Steven
机构：
[1] VCU Massey Canc Ctr, Richmond, VA USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Virginia Commonwealth Univ, Richmond, VA USA
[4] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19015
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
    Maher, Keri R.
    Shafer, Danielle
    Schaar, Dale
    Bandyopadhyay, Dipankar
    Deng, Xiaoyan
    Wright, John
    Piekarz, Richard
    Rudek, Michelle A.
    Harvey, R. Donald
    Grant, Steven
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [2] A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Murthy, Guru Subramanian Guru
    Saliba, Antoine N.
    Szabo, Aniko
    Harrington, Alexandra
    Abedin, Sameem
    Carlson, Karen
    Michaelis, Laura
    Runaas, Lyndsey
    Baim, Arielle
    Hinman, Alex
    Maldonado-Schmidt, Sonia
    Venkatachalam, Annapoorna
    Flatten, Karen S.
    Peterson, Kevin L.
    Schneider, Paula A.
    Litzow, Mark
    Kaufmann, Scott H.
    Atallah, Ehab
    HAEMATOLOGICA, 2024, 109 (09) : 2864 - 2872
  • [3] Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis
    Holkova, Beata
    Tombes, Mary Beth
    Shrader, Ellen
    Cooke, Sheryl S.
    Wan, Wen
    Sankala, Heidi
    Kmieciak, Maciej
    Roberts, John D.
    Garcia-Manero, Guillermo
    Grant, Steven
    BLOOD, 2011, 118 (21) : 1115 - 1115
  • [4] A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Saygin, Caner
    Larkin, Karilyn
    Blachly, James S.
    Orwick, Shelley
    Ngankeu, Apollinaire
    Gregory, Charles T.
    Phelps, Mitch A.
    Mani, Shylaja
    Walker, Alison
    Garzon, Ramiro
    Vasu, Sumithira
    Walsh, Katherine J.
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Grever, Michael R.
    Marcucci, Guido
    Byrd, John C.
    Blum, William
    Mims, Alice S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1457 - 1465
  • [5] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [6] Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
    Lee, Je-Hwan
    Faderl, Stefan
    Pagel, John M.
    Jung, Chul Won
    Yoon, Sung-Soo
    Pardanani, Animesh D.
    Becker, Pamela S.
    Lee, Howard
    Choi, Jeongeun
    Lee, Kyoungjune
    Kim, Minkyoung
    Cortes, Jorge E.
    BLOOD ADVANCES, 2020, 4 (09) : 2032 - 2043
  • [7] Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update
    Holkova, Beata
    Bose, Prithviraj
    Tombes, Mary Beth
    Shrader, Ellen
    Wan, Wen
    Weir-Wiggins, Caryn
    Stoddert, Elizabeth
    Sankala, Heidi
    Kmieciak, Maciej
    Roberts, John D.
    Garcia-Manero, Guillermo
    Grant, Steven
    BLOOD, 2012, 120 (21)
  • [8] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
    Murthy, Guru Subramanian Guru
    Kaufmann, Scott H.
    Szabo, Aniko
    Harrington, Alexandra M.
    Michaelis, Laura C.
    Abedin, Sameem
    Carlson, Karen
    Runaas, Lyndsey
    Longo, Walter L.
    Hinman, Alexander
    Maldonado-Schmidt, Sonia
    Thomas, Althea
    Baim, Arielle
    Litzow, Mark R.
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [9] A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
    Wartman, Lukas D.
    Fiala, Mark A.
    Hawkins, Emily
    Fletcher, Theresa
    Allen, Melissa
    Cashen, Amanda F.
    DiPersio, John F.
    Jacoby, Meagan
    Stockerl-Goldstein, Keith E.
    Pusic, Iskra
    Uy, Geoffrey L.
    Westervelt, Peter
    Vij, Ravi
    BLOOD, 2014, 124 (21)
  • [10] A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia
    Wartman, Lukas D.
    Fiala, Mark A.
    Fletcher, Theresa
    Hawkins, Emily R.
    Cashen, Amanda
    DiPersio, John F.
    Jacoby, Meagan A.
    Stockerl-Goldstein, Keith E.
    Pusic, Iskra
    Uy, Geoffrey L.
    Westervelt, Peter
    Vij, Ravi
    LEUKEMIA & LYMPHOMA, 2016, 57 (03) : 728 - 730
12345